CO2023002206A2 - Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2 - Google Patents

Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2

Info

Publication number
CO2023002206A2
CO2023002206A2 CONC2023/0002206A CO2023002206A CO2023002206A2 CO 2023002206 A2 CO2023002206 A2 CO 2023002206A2 CO 2023002206 A CO2023002206 A CO 2023002206A CO 2023002206 A2 CO2023002206 A2 CO 2023002206A2
Authority
CO
Colombia
Prior art keywords
trem2
agonist
agonists
colony
treatment
Prior art date
Application number
CONC2023/0002206A
Other languages
English (en)
Inventor
Matthew Brennan
Judith Dunn
Richard Fisher
Berkley A Lynch
Steven Robinette
Original Assignee
Vigil Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vigil Neuroscience Inc filed Critical Vigil Neuroscience Inc
Publication of CO2023002206A2 publication Critical patent/CO2023002206A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para tratar una enfermedad o trastorno causado por y/o asociado con una disfunción del CSF1R en un paciente humano, el método comprende administrar al paciente que lo necesita una cantidad eficaz de un compuesto que aumenta la actividad del receptor activador expresado en células mieloides 2 (TREM2). En algunas modalidades, el compuesto que aumenta la actividad de TREM2 es un agonista de TREM2. En algunas modalidades, el agonista de TREM2 es un agonista de molécula pequeña de TREM2 o un agonista de anticuerpo de TREM2.
CONC2023/0002206A 2020-08-05 2023-02-27 Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2 CO2023002206A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061315P 2020-08-05 2020-08-05
US202063129852P 2020-12-23 2020-12-23
PCT/US2021/071115 WO2022032293A2 (en) 2020-08-05 2021-08-05 Treatment of diseases related to colony-stimulating factor 1 receptor dysfunction using trem2 agonists

Publications (1)

Publication Number Publication Date
CO2023002206A2 true CO2023002206A2 (es) 2023-06-09

Family

ID=80117708

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0002206A CO2023002206A2 (es) 2020-08-05 2023-02-27 Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2

Country Status (13)

Country Link
US (1) US20220089726A1 (es)
EP (1) EP4192881A4 (es)
JP (1) JP2023536916A (es)
KR (1) KR20230061386A (es)
AU (1) AU2021320553A1 (es)
BR (1) BR112023002093A2 (es)
CA (1) CA3190581A1 (es)
CO (1) CO2023002206A2 (es)
CR (1) CR20230069A (es)
IL (1) IL300327A (es)
MX (1) MX2023001546A (es)
TW (1) TW202218683A (es)
WO (1) WO2022032293A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220110537A (ko) 2019-12-05 2022-08-08 알렉터 엘엘씨 항-trem2 항체 사용 방법
WO2023192288A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024052343A1 (en) * 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
WO2024097798A1 (en) * 2022-11-01 2024-05-10 Vigil Neuroscience, Inc. Anti-trem2 antibody and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106679B (zh) * 2014-08-08 2022-07-26 艾利妥 抗trem2抗体及其使用方法
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
UY38407A (es) * 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
JP2022513114A (ja) * 2018-11-26 2022-02-07 デナリ セラピューティクス インコーポレイテッド 脂質代謝調節不全の治療方法

Also Published As

Publication number Publication date
AU2021320553A1 (en) 2023-03-02
EP4192881A4 (en) 2024-08-14
JP2023536916A (ja) 2023-08-30
WO2022032293A2 (en) 2022-02-10
CR20230069A (es) 2023-08-16
KR20230061386A (ko) 2023-05-08
IL300327A (en) 2023-04-01
TW202218683A (zh) 2022-05-16
EP4192881A2 (en) 2023-06-14
BR112023002093A2 (pt) 2023-04-25
MX2023001546A (es) 2023-05-03
US20220089726A1 (en) 2022-03-24
CA3190581A1 (en) 2022-02-10
WO2022032293A3 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
CO2023002206A2 (es) Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2
BR112022018646A2 (pt) Composto agonista do receptor glp-1, composição farmacêutica compreendendo o mesmo, métodos para preparar o composto e uso do dito composto para prevenir ou tratar uma doença metabólica ou uma doença neurodegenerativa
RU2010108429A (ru) Регуляторы ммр-9 и их применение
Przeklasa-Muszyńska et al. Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients
CL2023003893A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcohólica.
Shan et al. Naringenin attenuates fibroblast activation and inflammatory response in a mechanical stretch-induced hypertrophic scar mouse model
UY39328A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
BR112023022264A2 (pt) Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
CL2023000856A1 (es) Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer
PE20240885A1 (es) Sales agonistas de sstr4
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
UY39608A (es) Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting
MX2023006397A (es) Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2.
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
CO2023013442A2 (es) Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
UY31786A1 (es) Inhibidores de la expresion y la actividad del pai-1 para el tratamiento de trastornos oculares
Prakash et al. Dopa responsive headache: Restless head syndrome or a cephalic variant of restless legs syndrome?
AR118191A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
Fahy et al. The adrenergic system in plastic and reconstructive surgery: physiology and clinical considerations
Najafpour et al. Vitamin C pre-medication enhances the anaesthetic effect of ketamine-xylazine combination in the rat
Abdulrahman et al. A study of α-Adrenoceptor agonists on porcine nasal and extra-nasal vasculature: insight into decongestant activity
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
AR123760A1 (es) Métodos para tratar el cáncer
AR123576A1 (es) Métodos para tratar el cáncer